Celldex Therapeutics - חוב לטווח קצר של החברה CLDX

Celldex Therapeutics (CLDX) develops unique antibodies to combat skin inflammation, leveraging patents for mast cell inhibitors. In collaboration with medical centers, the company is implementing precision therapy for cancer and immune dysfunction. The stock price trend on GURU.Markets demonstrates the 0.01 indicator. Business stability is guaranteed by a strong team of scientists, securely retained through a system of stock options.

This metric aggregates all Celldex Therapeutics (CLDX) liabilities with a maturity of up to one year. The metric reflects the current liquidity burden and the firm's ability to service operational loans. For the biotechnology sector with a diversified antibody portfolio, such funds are critical when conducting multi-profile clinical trials. Reducing debt strengthens the asset's financial stability. By analyzing the company's short-term debt dynamics, an investor assesses the balance between default risk and capital efficiency.